A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax
 added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction (
 a measure of brain shrinkage) and by clinical assessment scores to evaluate disease
 progression.
The protocol requires all participants to be treated with Avonex and in addition patients
 will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated
 neurological and clinical examinations are performed with laboratory tests to determine any
 possible adverse drug effects. The scaled neurologic examinations (EDSS and MSFC) and brain
 MRI's are done at regular intervals to evaluate possible treatment effects.
Inclusion Criteria:

 Relapsing-remitting multiple sclerosis

 -

 Exclusion Criteria:

 Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy
 -